Bristol-Myers Squibb agreed to acquire Celgene Corp. in a $74 billion cash-and-stock deal, to create a pharmaceutical giant that will rival the world’s biggest drugmakers. Bloomberg's Ruth David reports on "Bloomberg Daybreak: Americas." (Source: Bloomberg)